Predictors of reproductive health disorders

Authors

DOI:

https://doi.org/10.18370/2309-4117.2018.43.62-67

Keywords:

menstrual cycle disorders, polycystic ovary syndrome, phytotherapy, combined oral contraceptives, Tazalok

Abstract

«Bell» indicating a change in reproductive health is menstrual cycle disorders. 10–28% of the total number of endocrine gynecological diseases is menstrual cycle disorders, its clinical manifestations are absence of menstruation or rare or poor menstruation, as well as subclinical manifestations in the form of infertility and miscarriage. If there is irregular menstrual cycle, it is necessary to consider the diagnosis of polycystic ovary syndrome.

In the International evidence-based guideline for the assessment and management of polycystic ovary syndrome from 2018, a new treatment site appears phytotherapy, which has a hormone-correcting action. Its use is due to the fact that the polycystic ovaries syndrome is a life-long condition and need of long-term correction. For these purpose phytohormones without estrogenpositive activity flavonoids are used. Tazalok™ is one of such drugs. It blocks estrogen (androgen) receptors in the mammary glands, ovaries and uterus, normalizes estrogen-progestin balance (restores the hormonal balance).

It has been established that correlation between the hormones of the adipose tissue and the indices of the functional activity of the hypothalamic-adrenal and hypothalamic-oocyte systems in patients with polycystic ovaries syndrome is lost. In this regard, a study was conducted to investigate the possibility of using the multicomponent herbal preparation Tazalok™ in the complex treatment of polycystic ovary syndrome in women with obesity and normal level of ovarian androgens. As a result, it was found that the inclusion in the treatment scheme of this drug gives possible normalize the function of adipose tissue and improve its relationship with the pituitary-adrenal and pituitar-ovarian systems, normalize the menstrual cycle.

If it is necessary to restore the menstrual cycle the combined oral contraceptives should also be prescribed. They restore the menstrual cycle, which is the prevention of endometrial cancer, eliminating hypomenorrhea and hyperpolymenorrhea. The higher dose of estrogen in combined oral contraceptives is better kept the cycle, lead to less bleeding, but there is higher the thrombotic risk.

Author Biography

Т. Ф. Татарчук, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, chief of the Endocrine Gynecology Department

References

  1. Mallinson, R.J., De Souza, M.J. “Current perspectives on the etiology and manifestation of the «silent» component of the Female Athlete Triad.” Int J Womens Health 6 (2014): 451–67. DOI: 10.2147/IJWH.S38603
  2. Ibanez, L., Oberfield, S.E., Witchel, S., et al. “International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.” Horm Res Paediatr 88 (2017): 371–95. DOI: 10.1159/000479371
  3. Un Ju Jung, Myung-Sook Choi. “Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver DiseaseInt.” Int J Mol Sci 15.4 (2014): 6184–223. DOI: 10.3390/ijms15046184
  4. Reznikov, O.G., Tarasenko, L.V., Sinitsin, P.V., et al. “Anti-estrogenic activity of phytodrug Tazalokтм: results of experimental study.” Reproductive endocrinology 1.3 (2012): 90–2.
  5. Rice, S., Whitehead, S.A. “Phytoestrogens and breast cancer – promoters or protectors?” Endocr Relat Cancer 13.4 (2006): 995–1015.
  6. Sarkar, F.H., Adsule, S., Padhye, S., et al. “The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy.” Mini Rev Med Chem 6 (2006): 401–7.
  7. Tatarchuk, T.F., Ganzhii, I.Y., Pedachenko, N.Y., Kapshuk, I.M. “Modern features of non-hormonal treatment of polycystic ovary syndrome in obese women.” Reproductive endocrinology 5.13 (2013): 14–21.
  8. Fauser, B.C.J.M., et al. “Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.” Fertil Steril 97.1 (2012): 28–38.e25. DOI: 10.1016/j.fertnstert.2011.09.024
  9. Maybin, J.A., Critchley, H.O. “Menstrual physiology: implications for endometrial pathology and beyond.” Hum Reprod Update 21.6 (2015): 748–61.

Downloads

Published

2018-12-03

How to Cite

Татарчук, Т. Ф. (2018). Predictors of reproductive health disorders. REPRODUCTIVE ENDOCRINOLOGY, (43), 62–67. https://doi.org/10.18370/2309-4117.2018.43.62-67

Issue

No. 43 (2018)

Section

Reproductology

License

Copyright (c) 2018 Т. Ф. Татарчук

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.